On a preliminary basis, Coherus BioSciences (NASDAQ:CHRS) expects Q1 sales of Neulasta biosimilar UDENYCA (pegfilgrastim-cbqv) to be $36M – 38M, well above consensus of $2.8M.
The company will provide additional details during its Q1 conference call on May 9.
The European Commission approved the product in September 2018 followed by the FDA in November 2018.
Shares are up 5% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.